NCT05449444View on ClinicalTrials.gov

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

PHASE2UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Mast Cell Activation Syndrome
Interventions
DRUG

Masitinib 4.5 mg/kg/day

Masitinib 4.5 mg/kg/day

DRUG

Placebo

Matching placebo

OTHER

Best supportive care

Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, sodium cromoglicate, antidepressants, antileukotrienes, proton pump inhibitors, and corticosteroids.

DRUG

Masitinib 6.0 mg/kg/day

Masitinib 6.0 mg/kg/day

Trial Locations (4)

63304

RECRUITING

St Charles Clinical Research, Weldon Spring

Unknown

RECRUITING

Centre Hospitalier Universitaire Amiens-Picardie, Amiens

RECRUITING

Necker-Enfants Malades Hospital, Centre de référence des Mastocytoses (CEREMAST), Paris

RECRUITING

CHU Toulouse, Toulouse

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY